How many stocks are there of AstraZeneca?
The current number of stocks of AstraZeneca is 1.56 B undefined.
AstraZeneca Stocks 2024
AstraZeneca Stocks
1.56 B
Ticker
AZN.L
ISIN
GB0009895292
WKN
886455
In 2024, AstraZeneca had 1.56 B outstanding stocks, a 0% change from the 1.56 B stocks in the previous year.
The AstraZeneca Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 1.56 |
| 2028e | 1.56 |
| 2027e | 1.56 |
| 2026e | 1.56 |
| 2025e | 1.56 |
| 2024e | 1.56 |
| 2023 | 1.56 |
| 2022 | 1.56 |
| 2021 | 1.43 |
| 2020 | 1.31 |
| 2019 | 1.3 |
| 2018 | 1.27 |
| 2017 | 1.27 |
| 2016 | 1.27 |
| 2015 | 1.27 |
| 2014 | 1.26 |
| 2013 | 1.25 |
| 2012 | 1.26 |
| 2011 | 1.37 |
| 2010 | 1.45 |
| 2009 | 1.45 |
| 2008 | 1.45 |
| 2007 | 1.5 |
| 2006 | 1.57 |
| 2005 | 1.62 |
| 2004 | 1.68 |
AstraZeneca shares outstanding GB0009895292 · 886455
The number of shares was AstraZeneca in 2023 — This indicates how many shares 1.562 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue AstraZeneca earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates AstraZeneca's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of AstraZeneca’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AstraZeneca's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 1.68 B Aktien |
| 2005 | 1.62 B Aktien |
| 2006 | 1.57 B Aktien |
| 2007 | 1.5 B Aktien |
| 2008 | 1.45 B Aktien |
| 2009 | 1.45 B Aktien |
| 2010 | 1.45 B Aktien |
| 2011 | 1.37 B Aktien |
| 2012 | 1.26 B Aktien |
| 2013 | 1.25 B Aktien |
| 2014 | 1.26 B Aktien |
| 2015 | 1.27 B Aktien |
| 2016 | 1.27 B Aktien |
| 2017 | 1.27 B Aktien |
| 2018 | 1.27 B Aktien |
| 2019 | 1.3 B Aktien |
| 2020 | 1.31 B Aktien |
| 2021 | 1.43 B Aktien |
| 2022 | 1.56 B Aktien |
| 2023 | 1.56 B Aktien |
| 2024e | 1.56 B Aktien |
| 2025e | 1.56 B Aktien |
| 2026e | 1.56 B Aktien |
| 2027e | 1.56 B Aktien |
| 2028e | 1.56 B Aktien |
| 2029e | 1.56 B Aktien |
AstraZeneca Aktienanalyse
What does AstraZeneca do?
AstraZeneca PLC is a globally operating pharmaceutical company with its headquarters in England. The company was founded in 1999 through the merger of the Swedish company Astra AB and the British Zeneca Group PLC. Today, AstraZeneca employs more than 70,000 people and operates in over 100 countries. AstraZeneca specializes in the development, manufacturing, and marketing of pharmaceutical products. The company focuses primarily on oncology, cardiovascular and metabolic diseases, respiratory diseases, and autoimmune diseases. AstraZeneca is divided into various business segments. The oncology segment is a major focus of the company. Here, medications for various types of cancer are developed and manufactured. One particularly well-known product is the breast cancer medication Tamoxifen. In the cardiovascular and metabolic diseases segment, AstraZeneca offers various medications for heart and circulatory diseases as well as diabetes. One of the most well-known medications is Crestor, which is used to lower cholesterol levels. Another important area for AstraZeneca is respiratory diseases. Medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are developed and manufactured here. The medication Pulmicort is particularly well-known among asthma patients. Finally, AstraZeneca is also active in the field of autoimmune diseases. Medications against lupus erythematosus and rheumatoid arthritis are developed and manufactured here. AstraZeneca strives to improve healthcare worldwide through research and development of new medications. The company works closely with universities and research institutions and invests billions of dollars annually in research and development. AstraZeneca also pursues a sustainable business strategy and emphasizes acting environmentally and socially responsibly. The company is committed to reducing CO2 emissions and minimizing waste production. Over the years, AstraZeneca has received numerous awards and prizes, including the Sunday Times Innovation Award of the Decade, the Fierce Biotech Award for the medication Tagrisso, and the Prix Galien USA Award for Crestor. AstraZeneca aims to develop innovative medications that improve the lives of patients and advance healthcare worldwide. The company believes in a sustainable business strategy and actively promotes environmental and social responsibility. AstraZeneca will remain an important player in the global pharmaceutical industry in the future. AstraZeneca ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating AstraZeneca's Shares Outstanding
AstraZeneca's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in AstraZeneca’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding AstraZeneca’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in AstraZeneca’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about AstraZeneca stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of AstraZeneca are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of AstraZeneca evolved in recent years?
The number of shares of AstraZeneca has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. AstraZeneca as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of AstraZeneca?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does AstraZeneca pay?
Over the past 12 months, AstraZeneca paid a dividend of 2.35 USD . This corresponds to a dividend yield of about 1.79 %. For the coming 12 months, AstraZeneca is expected to pay a dividend of 1.01 USD.
What is the dividend yield of AstraZeneca?
The current dividend yield of AstraZeneca is 1.79 %.
When does AstraZeneca pay dividends?
AstraZeneca pays a quarterly dividend. This is distributed in the months of March, September, March, September.
How secure is the dividend of AstraZeneca?
AstraZeneca paid dividends every year for the past 26 years.
What is the dividend of AstraZeneca?
For the upcoming 12 months, dividends amounting to 1.01 USD are expected. This corresponds to a dividend yield of 0.77 %.
In which sector is AstraZeneca located?
AstraZeneca is assigned to the 'Health' sector.
Wann musste ich die Aktien von AstraZeneca kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AstraZeneca from 9/9/2024 amounting to 0.776 USD, you needed to have the stock in your portfolio before the ex-date on 8/8/2024.
When did AstraZeneca pay the last dividend?
The last dividend was paid out on 9/9/2024.
What was the dividend of AstraZeneca in the year 2023?
In the year 2023, AstraZeneca distributed 2.217 USD as dividends.
In which currency does AstraZeneca pay out the dividend?
The dividends of AstraZeneca are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The AstraZeneca stock can be added to a savings plan with the following providers: Scalable Capital and Consorsbank
Andere Kennzahlen von AstraZeneca
Our stock analysis for AstraZeneca Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AstraZeneca Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
